CD37 and non-Hodgkin lymphoma: Overall, the results of this study support the continued evaluation of IMGN529 as a novel CD37-targeting therapeutic in NHL, based on its manageable safety profile and encouraging signs of clinical efficacy, particularly in patients with DLBCL.